<DOC>
	<DOC>NCT02489838</DOC>
	<brief_summary>To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.</brief_summary>
	<brief_title>Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma</brief_title>
	<detailed_description>To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.</detailed_description>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Adults ≥ 18 years with no upper limit.Receiving Y90 Therasphere liver directed therapy Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y90) surgical resection not feasible at time of initiation of pretreatment workup &gt; 6 months projected life span ECOG 02 previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y90 radioembolization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Liver Neoplasma</keyword>
	<keyword>Lung Radiation dose</keyword>
</DOC>